# Clinical Trials Data EGFR - Document 56

# Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01394120

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Histologic diagnosis of pancreas adenocarcinoma\n\* Clinical stage IV\n\* Feasible patient for chemotherapy\n\* Availability of tumor tissue or possibility of a tumor biopsy to define therapeutic targets\n\* Informed written consent\n\nExclusion Criteria:\n\n\* Previous systemic treatment for advanced pancreas adenocarcinoma\n\* Contraindication to the administration of any of the drugs used in the study: capecitabine, 5Fluouracil, irinotecan, oxaliplatin, gemcitabine or erlotinib",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
This trial information doesn't explicitly state whether patients with EGFR mutations are eligible or ineligible. It requires a tumor biopsy to define therapeutic targets, implying that different targets, potentially including EGFR, might be considered. However, since the exclusion criteria lists erlotinib (a drug commonly used to target EGFR mutations), it's \*possible\* that EGFR-mutant patients may be excluded, especially if they've been previously treated with erlotinib.  
  
More information is needed to definitively determine eligibility. The presence of the EGFR mutation itself doesn't automatically qualify or disqualify a patient. It depends on how the trial uses the biopsy results to select targeted therapies within the study.